The North America Neurological Biomarkers Market should witness market growth of 13.5% CAGR during the forecast period (2022-2028).
Biomarkers, which are molecules that demonstrate the presence of a disease or dysfunction, are crucial for verifying diagnoses, selecting the most effective therapies, and tracking the development of diseases. Biomarkers for neurological disorders are one exception. Neurological markers can be found in cerebrospinal fluid (CSF), but seldom or in undetectable concentrations in blood.
The blood-brain barrier, which acts as the brain's own personal "security guard," closely monitors it to prevent harmful substances from entering it through the bloodstream. CSF can be used for neurological biomarkers, although doing so necessitates an invasive and uncomfortable lumbar puncture technique. These mysterious neural biomarkers are, nevertheless, gradually becoming clear. Neurological illnesses are becoming more manageable due to recent advancements in detection as well as the complete power of groupings of biomarkers, or biomarker signatures.
Using biomarkers as trial surrogate endpoints has a variety of benefits. The use of primary clinical outcomes in clinical trials can be extremely impractical or even unethical because they can occur so seldom, such as survival. Clear clinical objectives for many diseases, like survival or the recurrence of, say, a cardiovascular incident, may not emerge for many years after starting treatment. As more conclusive clinical data is gathered, biomarkers can give researchers interim information about the efficacy and safety of such treatments.
In the North American region, neurological problems are becoming more prevalent. Healthcare practitioners are making efforts to treat these conditions more effectively. Elderly people are becoming more prevalent in the neighborhood as well. By 2060, there will be 95 million Americans 65 and older, up from 52 million in 2018, due to increased R&D activities in the healthcare sector and the availability of neuromodulation devices on the market. The market is growing as more healthcare organizations invest in research and development.
The US market dominated the North America Neurological Biomarkers Market by Country in 2021; thereby, achieving a market value of $3,528.3 Million by 2028. The Canada market is exhibiting a CAGR of 16.1% during (2022-2028). Additionally, The Mexico market should witness a CAGR of 15% during (2022-2028).
Based on Type, the market is segmented into Proteomic, Genomic, Metabolomic and Others. Based on Application, the market is segmented into Alzheimer's Disease, Parkinson’s Disease and Multiple Sclerosis. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include F. HOFFMANN-LA ROCHE LTD., Bio-Rad Laboratories, Inc., Merck Group, PERKINELMER INC., Shimadzu corporation, Thermo Fisher Scientific, Inc., Quanterix Corporation, Neuro-Bio Ltd., BioMérieux S.A. and Myriad Genetics, Inc.
Biomarkers, which are molecules that demonstrate the presence of a disease or dysfunction, are crucial for verifying diagnoses, selecting the most effective therapies, and tracking the development of diseases. Biomarkers for neurological disorders are one exception. Neurological markers can be found in cerebrospinal fluid (CSF), but seldom or in undetectable concentrations in blood.
The blood-brain barrier, which acts as the brain's own personal "security guard," closely monitors it to prevent harmful substances from entering it through the bloodstream. CSF can be used for neurological biomarkers, although doing so necessitates an invasive and uncomfortable lumbar puncture technique. These mysterious neural biomarkers are, nevertheless, gradually becoming clear. Neurological illnesses are becoming more manageable due to recent advancements in detection as well as the complete power of groupings of biomarkers, or biomarker signatures.
Using biomarkers as trial surrogate endpoints has a variety of benefits. The use of primary clinical outcomes in clinical trials can be extremely impractical or even unethical because they can occur so seldom, such as survival. Clear clinical objectives for many diseases, like survival or the recurrence of, say, a cardiovascular incident, may not emerge for many years after starting treatment. As more conclusive clinical data is gathered, biomarkers can give researchers interim information about the efficacy and safety of such treatments.
In the North American region, neurological problems are becoming more prevalent. Healthcare practitioners are making efforts to treat these conditions more effectively. Elderly people are becoming more prevalent in the neighborhood as well. By 2060, there will be 95 million Americans 65 and older, up from 52 million in 2018, due to increased R&D activities in the healthcare sector and the availability of neuromodulation devices on the market. The market is growing as more healthcare organizations invest in research and development.
The US market dominated the North America Neurological Biomarkers Market by Country in 2021; thereby, achieving a market value of $3,528.3 Million by 2028. The Canada market is exhibiting a CAGR of 16.1% during (2022-2028). Additionally, The Mexico market should witness a CAGR of 15% during (2022-2028).
Based on Type, the market is segmented into Proteomic, Genomic, Metabolomic and Others. Based on Application, the market is segmented into Alzheimer's Disease, Parkinson’s Disease and Multiple Sclerosis. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include F. HOFFMANN-LA ROCHE LTD., Bio-Rad Laboratories, Inc., Merck Group, PERKINELMER INC., Shimadzu corporation, Thermo Fisher Scientific, Inc., Quanterix Corporation, Neuro-Bio Ltd., BioMérieux S.A. and Myriad Genetics, Inc.
Scope of the Study
By Type
- Proteomic
- Genomic
- Metabolomic
- Others
By Application
- Alzheimer's Disease
- Parkinson’s Disease
- Multiple Sclerosis
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- F.HOFFMANN-LA ROCHE LTD.
- Bio-Rad Laboratories, Inc.
- Merck Group
- PERKINELMER INC.
- Shimadzu corporation
- Thermo Fisher Scientific, Inc.
- Quanterix Corporation
- Neuro-Bio Ltd.
- BioMérieux S.A.
- Myriad Genetics, Inc.
Unique Offerings
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. North America Neurological Biomarkers Market by Type
Chapter 4. North America Neurological Biomarkers Market by Application
Chapter 5. North America Neurological Biomarkers Market by Country
Chapter 6. Company Profiles
Companies Mentioned
- F. HOFFMANN-LA ROCHE LTD.
- Bio-Rad Laboratories, Inc.
- Merck Group
- PERKINELMER INC.
- Shimadzu corporation
- Thermo Fisher Scientific, Inc.
- Quanterix Corporation
- Neuro-Bio Ltd.
- BioMérieux S.A.
- Myriad Genetics, Inc.
Methodology
LOADING...
